FDA opens US to Lyrica generics
24-07-2019
Pfizer expects $1.9bn loss due to patent expirations
31-07-2018
Pfizer allows Teva’s generic Viagra
19-12-2013
31-01-2019
no_limit_pictures / iStockphoto.com
American pharmaceutical company Pfizer warned investors of little revenue growth to come in 2019, owing partly to expiring exclusivity rights on drugs including Viagra and the seizure medicine Lyrica.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Pfizer, Viagra, generics, biosimilars, patent expiration, exclusivity, pharmaceuticals, Lyrica
FDA opens US to Lyrica generics
24-07-2019
Pfizer expects $1.9bn loss due to patent expirations
31-07-2018
Pfizer allows Teva’s generic Viagra
19-12-2013